These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20813817)

  • 1. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
    Russell MR; Liu Q; Fatatis A
    Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.
    Matsuo K; Nishimura M; Komurov K; Shahzad MM; Ali-Fehmi R; Roh JW; Lu C; Cody DD; Ram PT; Loizos N; Coleman RL; Sood AK
    Gynecol Oncol; 2014 Jan; 132(1):166-75. PubMed ID: 24183729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
    Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
    Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.
    Roh JW; Huang J; Hu W; Yang X; Jennings NB; Sehgal V; Sohn BH; Han HD; Lee SJ; Thanapprapasr D; Bottsford-Miller J; Zand B; Dalton HJ; Previs RA; Davis AN; Matsuo K; Lee JS; Ram P; Coleman RL; Sood AK
    Clin Cancer Res; 2014 May; 20(10):2740-50. PubMed ID: 24634380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 7. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor.
    Dolloff NG; Russell MR; Loizos N; Fatatis A
    Cancer Res; 2007 Jan; 67(2):555-62. PubMed ID: 17234763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
    Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
    Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
    Böckelmann LC; Freytag V; Ahlers AK; Maar H; Gosau T; Baranowsky A; Schmitz R; Pantel K; Schumacher U; Haider MT; Lange T
    Bone; 2023 Jun; 171():116741. PubMed ID: 36934984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
    Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
    Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
    Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
    Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
    Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.
    Shah GD; Loizos N; Youssoufian H; Schwartz JD; Rowinsky EK
    Cancer; 2010 Feb; 116(4 Suppl):1018-26. PubMed ID: 20127943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.
    Liu Q; Jernigan D; Zhang Y; Fatatis A
    Chin J Cancer; 2011 Sep; 30(9):612-9. PubMed ID: 21880182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
    Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
    Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
    Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
    Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: targeted therapy for prostate cancer metastases to bone.
    Coleman R
    Nat Rev Urol; 2011 May; 8(6):296-8. PubMed ID: 21587226
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.